Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

Related Issuers

PX TALK: Almirall E250m 5NC2 sr notes 2.25-2.50%

HYC US Market: Commentary - M&AHYC European Market: Commentary - M&AHYC European Market: Deal Flow - General

Almirall SA EUR250m 144A/Reg S sr notes due 2026 (5y). NC2 (50%,25%,par). Ba3/BB- (stable/stable). Via BNP/JPM (B&D) jt glocos/BBVA/BofA/Caixa/Santander jt books. No reg rights. List lux. NY law. IPT: mid 2s.

Px talk: 2.25%-2.50%.

Did investor call at 11am UKT Mon (virtual 1x1s Mon-Weds). Books close at 12pm UKT today. Pricing today UK afternoon. UOP: along with EUR5m cash on hand, to repay its EUR250m 0.25% cvt notes due 12/14/21. Biz: Almirall is a publicly listed pharmaceutical company that researches, develops, produces and markets a fairly diversified portfolio of in-house developed drugs and in-licensed drugs in therapeutic areas including dermatology, respiratory, gastrointestinal and pain relief. HQ: Barcelona, Spain.

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.